Significant advances in the molecularly targeted therapies have been made to treat lung adenocarcinoma patients harboring mutant EGFR, ALK, RET,ROS1, BRAF, MET, NTRK-1 & 2, ERBB2, and FGFR3 [6–8]. Here, EGFR is linked to lung adenocarcinoma.